Effects of a metabotropic glutamate2/3 receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: Preliminary results

Psychopharmacology

Volumn 179, Issue 1, 2005, Pages 310-315

  Kellner, Michael ^a   Muhtz, Christoph ^a   Stark, Kristina ^a   Yassouridis, Alexander ^b   Arlt, Josef ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

ACTH; Anxiety; CCK 4; Cortisol; LY544344; Metabotropic glutamate receptors; Panic; Prolactin

Indexed keywords

2 [(2' AMINO)PROPIONYL]AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; CORTICOTROPIN; EGLUMETAD; METABOTROPIC RECEPTOR AGONIST; PLACEBO; TALAGLUMETAD; TETRAGASTRIN; UNCLASSIFIED DRUG;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HORMONE RELEASE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STRESS; TRANQUILIZING ACTIVITY;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANXIETY; BICYCLO COMPOUNDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID AGONISTS; HUMANS; HYDROCORTISONE; MALE; PANIC DISORDER; PROLACTIN; RECEPTORS, METABOTROPIC GLUTAMATE; TETRAGASTRIN;

EID: 17744390351     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2025-1     Document Type: Article

References (33)

1. Bieck PR, Jhee SS, Ledent E, Mackie AE, Patil S, Perkins EJ, Potter WZ (2003) Application of continuous cerebrospinal fluid (CSF) collection in man to assess the glutamate receptor agonist LY354740 pharmacokinetics and its effect on biomarker and proteomics. Abstract, conference on in vivo methods, Stockholm, Sweden
2. Boyle J, Trick S, Soo-ampon S, Lilley S, Levine L, Hindmarch I (2003) Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY53, compared to lorazepam in normal volunteers. Eur Neuropsychopharmacol 13(Suppl 4):S365
3. Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48:603-610
4. Chojnacka-Wojcik E, Klodzinska A, Pile A (2001) Glutamate receptor ligands as anxiolytics. Curr Opin Invest Drugs 2:1112-1119
5. Dillon D, Gorman JM, Liebowitz MR, Fyer AJ, Klein DF (1987) The measurement of lactate-induced panic anxiety. Psychiatry Res 20:97-105
6. Ferris P, Seward E, Dawson GR (2001) Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15:76-82
7. Grillon C, Cordova J, Levine LR, Morgan CA (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 168:446-454
8. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660
9. Hiller W, Zaudig M, Mombour W, Bronisch T (1993) Routine psychiatric examinations guided by ICD-10 diagnostic checklists (International Diagnostic Checklists). Eur Arch Psychiatr Clin Neurosci 242:218-223
10. Holden C (2003) Psychiatric drugs. Excited by glutamate. Science 300:1866-1868
11. Johnson MP, Chamberlain M (2002) Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268. Neuropharmacology 43:799-808
12. Kellner M, Yassouridis A, Jahn H, Wiedemann K (1997) Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 133:55-61
13. Kellner M, Yassouridis A, Hua Y, Wendrich M, Jahn H, Wiedemann K (2002) Intravenous C-type natriuretic peptide augments behavioural and endocrine effects of cholecystokinin tetrapeptide in healthy man. J Psychiatr Res 36:1-6
14. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pile A (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839
15. Koszycki K, Zacharko RM, Le Melledo JM, Young SN, Bradwejn J (1996) Effect of acute tryptophan depletion on behavioural, cardiovascular, and hormonal sensitivity to cholecystokinintetrapeptide in healthy volunteers. Biol Psychiatry 40:648-655
16. Le Mellédo JM, Bradwejn J, Koszycki D, Boulanger JP, Cadieux A, Ballavance G, Bichet DG (1997) The role of the β-adrenergic system in behavioural and neuroendocrine response to CCK-4. Abstract, NCDEU Annual Meeting, Miami, Fla.
17. 2 challenge in patients diagnosed with panic disorder. Neuropharmacology 43:294-295
18. Maione S, Palazzo E, de Novellis V, Stella I, Leyva J, Rossi F (1998) Metabotropic glutamate receptors modulate serotonin release in the rat periaqueductal gray matter. Naunyn Schmiedeberg's Arch Pharmacol 358:411-417
19. Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 130:10078-10158
20. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BTG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-di-carboxylate: a potent, selective, systematically active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537
21. Pin J-P, Duvoisin R (1995) The metabotropic glutamate receptors: structure and function. Neuropharmacology 34:1-26
22. Scaccianoce S, Matrisciano F, Del Biance P, Caricasole A, Di Giorgi Gerevini V, Cappuccio I, Melchiorri D, Battaglia G, Nicoletti F (2003) Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. Neuropharmacology 44:555-561
23. Schoepp DD (1994) Novel functions for subtypes of metabotropic glutamate receptors. Neurochem Int 24:439-449
24. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL, Burnett JP, Belagaje R, Bleakiman D, Monn JA (1997a) Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist. Naunyn Schmiedeberg's Arch Pharmacol 358:175-180
25. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL, Burnett JP, Belagaje R, Bleakman D, Monn JA (1997b) LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36:1-11
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorin P, Janavas J, Weiller E, Hergueta T, Baker R, Dunbar GC (1989) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnositic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33
27. Shekhar A, Keim SR (2000) LY35470, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39:1139-1146
28. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997) Effects of citalopram on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatr Neurosci 22:332-340
29. Tatarczynska E, Klodzinska A, Kroczka B, Chojnacka-Wojcik E, Pilc A (2001) The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology 158:94-99
30. Tizzano JP, Griffey KI, Schoepp DD (2002) The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374
31. Walker DL, Davis M (2002) The role of amygdale glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 71:379-392
32. Wiedemann K, Jahn H, Yassouridis A, Kellner M (2001) Anxiolytic like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks. Arch Gen Psychiatry 58:371-377
33. Zwanzger P, Eser D, Aicher S, Schüle C, Bagai TC, Padberg F, Ella R, Möller HJ, Rupprecht R (2003) Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamicpituitary-adrenal- axis activity: a placebo-controlled study. Neuropsychopharmacology 28:979-984